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Summary Interest in the years of reproductive changes for women with epilepsy
(WWE), specifically perimenopause, menopause and postmenopause has been emer-
ging in the epilepsy community. This article discusses evidence for changes in seizure
frequency during perimenopause and postmenopause. Further, a catamenial epilepsy
pattern during the reproductive years may be a hallmark for the observed seizure
frequency change during these years; that is, an increase at perimenopause but a
decrease at menopause. This finding implies that a subset of WWE are particularly
susceptible to endogenous reproductive hormonal changes. An adverse effect on
seizure frequency with the use of hormone replacement therapy (HRT) during
postmenopause for WWE was reported in questionnaires, and was later borne out
in a clinical trial. The laboratory counterpart of this human trial, HRT in ovariecto-
mized rodent seizure models, shows that estrogen and progesterone are neuropro-
tective and do not uniformly increase seizure frequency. Possible reasons for the
discrepancy between ‘‘the lab and the clinic’’ are presented. Strategies for managing
HRT in symptomatic postmenopausal WWE using estrogenic and progestogenic com-
pounds that may be less likely to promote seizures are discussed.
# 2007 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.Introduction
Women with epilepsy (WWE) in perimenopause,
menopause and perimenopause present a practical
clinical challenge as well a complex hormonal brain
environment in which to explore the relationships
between hormones and epilepsy. In this brief review,
associations between these life changes in WWE,* Correspondence to: Comprehensive Epilepsy Center, Room K-
615, 525 East 68th Street, Weill Cornell Medical College, New
York, NY, United States. Tel.: +1 212 746 2346;
fax: +1 212 746 8845.
E-mail address: clharden@med.cornell.edu.
1059-1311/$ — see front matter # 2007 British Epilepsy Association
doi:10.1016/j.seizure.2007.11.026seizure frequency and the use of hormone replace-
ment therapy (HRT) will be presented. The labora-
tory evidence either supporting or refuting the
changes in seizure frequency found in these studies
will be discussed. Finally, suggestions for manage-
ment of mature WWE will be put forth.Hormone replacement therapy in
women with epilepsy
The idea that HRT could affect seizure activity in
WWE was first suggested in a questionnaire study
intended to obtain preliminary information about. Published by Elsevier Ltd. All rights reserved.
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course of epilepsy. A secondary aim of the ques-
tionnaire was to assess whether a history of a cat-
amenial seizure pattern would influence this
course.1 Questionnaires were sent to WWE using a
mailing list from the local Epilepsy Foundation chap-
ter and only those responses from women currently
in menopause or perimenopause who did not have
antepileptic drug (AED) changes during these life
epochs, and who gave clear and legible responses
were used. They provided information regarding the
course of their epilepsy and treatment, seizure
type, relationship of seizures to menses during their
reproductive years, specifically the occurrence of
seizures in the week before menses and at the onset
of menses (catamenial seizure pattern type 12), and
the use of HRT. The relationship of HRT to seizure
occurrence was not specifically queried in this
questionnaire. Statistical analysis was performed
by using Pearson Chi-square with 95% confidence
limits.
Thirty-nine perimenopausal women (ages 38—55
years) as defined by a recent change in menstrual
pattern and the occurrence of ‘‘hot flushes’’
responded. Nine subjects reported no change in
seizures at perimenopause, 5 reported a decrease
in seizure frequency and 25 reported an increase.
Eight (15%) subjects took synthetic HRTand 28 (72%)
reported having a catamenial seizure pattern before
menopause. HRT had no significant effect on sei-
zures; however, a history of catamenial seizure
pattern was significantly associated with an increase
in seizures at perimenopause ( p = 0.02) (see Fig. 1).
Considering that estrogen is generally proconvulsant
and progesterone is anticonvulsant in animal seizure
models,3 it is possible that the reproductive hormo-
nal changes in perimenopause could contribute to
increased seizures. During perimenopause, estrogen
levels remain unchanged or may rise with age until
the onset of menopause, presumably in response toFigure 1 Perimenopausal women–—epilepsy pattern.
*Significantly associated with an increase in seizures
( p = 0.02).the elevated FSH levels. However, the cyclic pro-
gesterone elevation during the luteal phase of the
menstrual cycle gradually becomes less frequent
throughout perimenopause, resulting in increasing
rates of anovulatory cycles.4 The elevation of the
estrogen-to-progesterone ratio may contribute to
the increase in seizure frequency at perimenopause
for some WWE.
Forty-two postmenopausal women (ages 41—86
years) as defined as one year without menses
responded. Twelve subjects reported no change in
seizures at menopause, 17 reported a decrease in
seizure frequency and 13 reported an increase.
Sixteen (38%) took synthetic HRT. Sixteen (38%)
additional subjects (having some overlap with the
HRT group) reported having a catamenial seizure
pattern before menopause. HRT was significantly
associated with an increase in seizures during peri-
menopause ( p = 0.001). A history of catamenial
seizure pattern was significantly associated with a
decrease in seizures at menopause ( p = 0.013) (see
Fig. 2).
These pilot data suggest that WWE may be more
likely than not to have an increase in seizures at
perimenopause and therefore may need more care-
ful monitoring at this time for AED adjustment or
AED change. Further, these findings indicate that
catamenial seizure pattern may be associated with
seizure decrease during menopause but with an
increase during perimenopause. This is consistent
with the idea that a subset of WWE are especially
sensitive to endogenous hormonal changes, asso-
ciated with increased seizures in response to hor-
monal fluctuations, but decreased seizures when
reproductive hormones stabilize. Finally, the results
suggest that synthetic HRT may be associated with
an increase in seizure frequency in menopausal
WWE. The important implications of this finding
prompted further study whether such an effect of
endogenous hormones on WWE was present.Figure 2 Postmenopausal women–—epilepsy patten.
*Hormone replacement therapy was associated with sei-
zure exacerbation ( p = 0.001). **Significantly associated
with a decrease in seizures ( p = 0.013).
178 C.L. HardenThe study of HRT in WWE was designed to deter-
mine whether adding HRT to the medication regi-
men of postmenopausal WWEwas associated with an
increase in seizure frequency.5 The study design was
a randomized, double-blind, placebo-controlled
trial of the effect of HRT on seizure frequency in
postmenopausal WWE, taking stable doses of anti-
epileptic drugs (AEDs), and within 10 years of their
last menses. After a 3-month prospective baseline,
subjects were randomized to placebo, Prempro
(0.625 mg of conjugated equine estrogens plus
2.5 mg of medroxyprogesterone acetate or CEE/
MPA) daily or double-dose CEE/MPA daily for a 3-
month treatment period. This particular form of
HRT was chosen for the trial because it was a very
popular and widely used form of HRT at the time.
Further, it was the treatment in the large, long-
term, placebo-controlled The Women’s Health
Initiative (WHI) study which looked at multiple
medical outcomes. Therefore, it was thought that
the use of this complex equine-derived estrogen and
this synthetic progestin in the WWE study would be
appropriate in the WWE trial because the results
could be extrapolated to the general population of
WWE. Further, this was the most commonly used
form of HRTreported in the questionnaire study. The
results were analyzed by Chi-square for trend, com-
paring the numbers of subjects whose seizure fre-
quency increased on treatment compared to
baseline versus the number of subjects whose sei-
zures did not increase across treatment arms.
Unfortunately, the first report of the WHI results
in 2002 was the that HRT in the form of CEE/MPAwas
associated with an increased risk for breast cancer
and stroke.6 These results were surprising in the
light of the long use of this compound, and lead to
early termination of the WHI trial as well as the HRT
in WWE study due to safety concerns.
Therefore, only 21 subjects were randomized
after completing baseline; the results are discussed
herein. The subjects’ ages ranged from 45 to 62
years (mean, 53 years; S.D., 5) and the number of
AEDs used ranged from none to three (median, one).
There were no differences in baseline characteris-
tics including age, age at menopause, number of
AEDs and complex partial and generalized seizure
frequency between the three treatment arms. How-
ever, the double dose CEE/MPA arm had significantly
more simple partial seizures during baseline than
the other treatment arms. Most subjects had no
seizures of any type during baseline.
On HRT treatment compared to placebo, there
was a significant trend toward increased seizures in
a dose-related manner using several seizure fre-
quency analyses. Five (71%) of seven subjects taking
double-dose CEE/MPA had a worsening seizure fre-quency of at least one seizure type, compared with
four (50%) of eight taking single-dose CEE/MPA and
one (17%) of six taking placebo (p = 0.05). An
increase in seizure frequency of the subject’s most
severe seizure type was associated with increasing
CEE/MPA dose ( p = 0.008). An increase in complex
partial seizure frequency also was associated with
increasing CEE/MPA dose (p = 0.05) (see Table 1).
Total seizure number approached significance with
increasing CEE/MPA ( p = 0.10).
Two subjects taking lamotrigine had a decrease in
lamotrigine levels of 25—30% while taking CEE/MPA.
This is likely due induction of uridine diphosphate-
glucuronosyltransferase (UGT) 1A4 by ethinyl estra-
diol, which is the main metabolic enzyme for lamo-
trigine, as occurs with hormonal contraceptives.7
Therefore, although the small numbers of subjects
in this study may limit its generalizability, the
results indicate that CEE/MPA is associated with a
dose-related increase in seizure frequency in post-
menopausal WWE. Further, the lamotrigine clear-
ance may be increased with HRT as well.Menopause and HRT in animal seizure
models
Interestingly, although these two clinical reports
have consistent outcomes of adverse effects on
seizure, there are not supportive laboratory coun-
terparts of these findings. Ovariectomy in adult
female rats, as an analogous state to menopause,
is associated with increased seizure activity in using
standard seizure-producing techniques. Using the
pilocarpine model, ovariectomized rats showed a
significantly more rapid progression to status epi-
lepticus compared with intact animals.8 With an
NMDA seizure-induction model, ovariectomized rats
had a significantly increased total seizure number
and more severe hippocampal damage compared
with age-matched intact female animals.9
As an analogous state to HRT during menopause,
is there laboratory evidence for how hormone repla-
cement affects seizure activity in a rodent postme-
nopausal model? Again, contrary to the findings of
the recent human studies, several experiments have
shown an overall neuroprotective effect of estrogen
and progesterone, but little effect on seizure fre-
quency. In a kainate-induced model, estrogen pre-
treatment had no effect on seizure severity but
significantly decreased ‘‘spread,’’ neuronal loss
and mortality in ovariectomized rats compared with
ovariectomized rats without pretreatment. Proges-
terone pretreatment in this model had a slightly
different effects; it decreased seizure severity and
hippocampal damage.10 In the NMDA-induced
Hormone replacement therapy: Will it affect seizure control and AED levels? 179
Ta
b
le
1
N
u
m
b
e
r
o
f
su
b
je
ct
s
w
it
h
in
cr
e
as
e
in
se
iz
u
re
fr
e
q
u
e
n
cy
b
y
tr
e
at
m
e
n
t
ar
m
(N
=
21
)
Tr
e
at
m
e
n
t
gr
o
u
p
Si
m
p
le
p
ar
ti
al
a
C
o
m
p
le
x
p
ar
ti
al
b
Se
co
n
d
ar
il
y
ge
n
e
ra
li
ze
d
To
ta
l
n
u
m
b
e
r
o
f
Sz
c
A
n
y
Sz
ty
p
e
d
M
o
st
se
ve
re
Sz
ty
p
e
e
n
%
n
%
n
%
n
%
n
%
n
%
P
la
ce
b
o
(n
=
6)
1
16
.7
0
0.
0
0
0.
0
0
0.
0
1
16
.7
0
0.
0
Si
n
gl
e
C
E
E
/M
PA
(n
=
8)
3
37
.5
1
12
.5
0
0.
0
3
37
.5
4
50
.0
3
37
.5
D
o
u
b
le
C
E
E
/M
PA
(n
=
7)
1
14
.3
3
42
.9
1
14
.3
3
42
.9
5
71
.4
5
71
.4
C
E
E
,
C
o
n
ju
ga
te
d
e
q
u
in
e
e
st
ro
ge
n
s;
M
PA
,
m
e
d
ro
xy
p
ro
ge
st
e
ro
n
e
ac
e
ta
te
.
a
p
=
0.
88
b
y
C
h
i-
sq
u
ar
e
te
st
fo
r
tr
e
n
d
.
b
p
=
0.
05
b
y
C
h
i-
sq
u
ar
e
te
st
fo
r
tr
e
n
d
.
c
p
=
0.
10
b
y
C
h
i-
sq
u
ar
e
te
st
fo
r
tr
e
n
d
.
d
p
=
0.
05
b
y
C
h
i-
sq
u
ar
e
te
st
fo
r
tr
e
n
d
.
e
p
=
0.
00
8
b
y
C
h
i-
sq
u
ar
e
te
st
fo
r
tr
e
n
d
.model, estrogen pretreatment decreased total sei-
zure number in ovariectomized rats compared with
ovariectomized rats without pretreatment; and in
fact, estrogen replacement restored seizure number
tothatof the intact state.6 In the lithium—pilocarpine
model of status epilepticus, estrogenpretreatment is
neuroprotective in ovariectomized rats compared
with sham-treated ovariectomized controls.11
Several factors may explain the seeming differ-
ence in these laboratory results to the effects of HRT
on menopausal WWE. First, ovariectomized rats
liley do not have an analogous hormonal brain milieu
to naturally menopausal women. The rats were not
in surgical postmenopause for a long period of time
prior to the experiments, a matter of days in most
experiments, in contrast to postmenopausal women
who had years to develop changes to neurons and
glia following hormone withdrawal. Second, the
doses of HRT used by menopausal women are rela-
tively higher than the doses used in these laboratory
experiments. Finally, it is possible that the synthetic
progestin, MPA, used in human studies could account
for the adverse effects on seizures. Little is known
regarding the effects of MPA on brain excitability. It
is widely accepted that estrogen generally facili-
tates seizure activity, while progesterone (through
the action of its reduced metabolite, allopregnano-
lone) has anticonvulsant properties.3 However, MPA
clearly has a different profile of activity in the brain,
is not metabolized to allopregnanolone and is not
neuroprotective in rodents.12 In one study of ovar-
iectomized rats with and without estrogen replace-
ment, the effect of progesterone versus MPA
pretreatment on kainate-induced seizures was eval-
uated with quite differing results for the two com-
pounds. Both progesterone and MPA blocked the
neuroprotective effects of estrogen in these experi-
ments (a result differing from previous experiments
for progesterone), and seizure severity was worse
but not significantly so in the MPA-treated group.13
Therefore, several factors, including the possibility
of an adverse effect of MPA on seizures, may account
for the inability to readily translate this paradigm
from the lab to the clinic, or in this case, from the
clinic back to the lab.
Since progesterone in its natural form in the FDA-
approved form of Prometrium is readily available, it
is a reasonable option as the progestin component
when HRT is needed for WWE, especially since there
is evidence that it has active anticonvulsant proper-
ties.14 For the estrogen component, a simplified
estrogen compound, such as compound, 17-b-estra-
diol could be considered as well. Clinicians must
consider these options since HRT will certainly be
needed for some WWE; sleep deprivation related to
‘‘hot flushes’’ can have an adverse effect on seizure
180 C.L. Hardenfrequency and in such cases, HRT may be beneficial
by permitting adequate sleep.15Conclusion
A risk of increased seizures with HRT consisting of
CEE and MPA appears to be present in postmeno-
pausal WWE. This was found in a cross-sectional
questionnaire as well as a randomized, double-
blinded, placebo-controlled clinical trial. Yet
WWE will need to take HRT at times, for sympto-
matic relief and to allow adequate sleep when ‘‘hot
flushes’’ are disruptive. The author suggests that a
combination of a single estrogenic compound such
as 17-b-estradiol along with natural progesterone
be considered in this clinical scenario.References
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